Supported by one trial

One controlled phase 3 trial met its main goal. Confirmed needs a second trial or regulatory approval for this use.

Fish oil: reduce relapses and new lesions in relapsing MS

relapsing MS · Vitamin D and nutritional supplements

One controlled phase 3 trial met its main goal. It needs a second trial or regulatory approval to count as confirmed.

Trials
1
Running now
0
Controlled phase 2/3 trials
1
People in controlled trials
220

How the verdict was reached

Supported in phase 3: One controlled phase 3 trial met its main goal. Confirmed needs a second trial or regulatory approval for this use.

TrialPhaseParticipantsStartedResultCounted
Fish oil, phase 3Phase 32202016Met its main goal

For the intention-to-treat analyses Neuroaspis plp10 significantly reduced the ARR by 80%, (RRR, 0.20; 95% CI: 0.09 to 0.45; p=0.0001) and the risk of sustained progression of disability by 73% (HR, 0.27; 95% CI: 0.09 to 0.83; p=0.022) versus placebo, at 2 years.

Paper abstract		Counted

Counted: 1. Will count later: 0. Not counted: 0.

Lab evidence

Lab studies in animals or cells. Results in animals often do not hold in people, and these studies never change the status of an idea.

Loading lab studies…

Loading reviews and guidelines…

History

  • Nov 2026Status changed from Results pending to Supported by one trial
  • Nov 2026Status changed from Being tested to Results pending
  • Oct 2026First listed as Being tested

Related hypotheses

Assembled by software from public sources.